Merck & vs Gilead Sciences: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Merck & Company Inc (MRK)

Q3 202630 Jun – 30 Sep 2026

▲3

Merck's Q3: Pipeline Wins and Guidance Raise Offset Keytruda Threats

Keytruda Label Expansions and Phase 3 Wins Merck expanded Keytruda's labels in breast and bladder cancer and reported a Phase 3 win in endometrial cancer. These broaden use and support sales growth, helping offset looming competition.
Shows continued growth for Merck's top drug, a key positive for the quarter.
FDA Approves LIPFENDRA, First Oral PCSK9 Inhibitor Merck won FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for high cholesterol. This opens a new market and diversifies revenue beyond oncology.
A major new product approval that adds a new growth driver.
Q2 Beat and Raised Full-Year Guidance Merck beat Q2 estimates with $16.61 billion revenue and raised full-year guidance to $66.3–67.3 billion. The strong results and outlook boosted investor confidence.
Directly reflects financial performance and management confidence.
Keytruda Competitive Threats and Other Headwinds Keytruda faces threats from ivonescimab, AstraZeneca's $2 billion Summit investment, and a pre-2028 biosimilar. Also, a congressional probe, generic Janumet XR, lost COVID revenue, and acquisition charges weighed.
Highlights the main risks that could pressure Merck's stock despite positives.

September 202630 Aug – 30 Sep 2026

▲2▼1

Merck's mRNA vaccine and new cholesterol drug shine, but Keytruda threats loom

FDA approves LIPFENDRA, first oral PCSK9 cholesterol drug The FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, offering a new growth driver in a large market and potentially boosting Merck's revenue outlook.
This is a new product approval that expands Merck's commercial portfolio.
Pipeline expansions and label wins Merck advanced its pipeline with tulisokibart, a KRAS licensing deal, and oral delivery technology, while gaining label expansions for Keytruda, Winrevair, and Welireg, offsetting patent-cliff worries.
These moves strengthen Merck's long-term growth prospects and diversify its revenue base.
Keytruda faces competitive threats Keytruda faces mounting threats: Summit's ivonescimab beat it in lung cancer survival, AstraZeneca invested $2 billion in Summit, and a pembrolizumab biosimilar is coming before the 2028 patent expiry.
Keytruda is Merck's top-selling drug, so competition could significantly hurt future revenue.

Latest27 Sep – 30 Sep 2026

▲3▼1

Merck's pipeline wins and deals offset Keytruda competition

Tulisokibart hits Phase 2b goal in skin disease Merck's anti-TL1A drug tulisokibart met its main goal in a mid-stage hidradenitis suppurativa trial, with 72% of high-dose patients responding versus 35% on placebo. This is the first positive Phase 2 result for this drug class in dermatology, opening a new growth area beyond cancer and supporting the stock.
New clinical win shows pipeline diversification beyond Keytruda, a key positive for future revenue.
Merck licenses KRAS cancer drug for up to $2.13B Merck paid $400 million upfront for global rights to SciBrunch's SPR2015, a preclinical KRAS G12D inhibitor for pancreatic, colorectal and lung cancers, with total deal value up to $2.13 billion. This adds a promising early cancer asset, though it will cause a $0.13 per share charge in Q3 results.
New licensing deal expands oncology pipeline, a strategic positive despite a small near-term earnings hit.
Oral drug delivery tech enters human testing MSD began a Phase 1 trial of a proprietary drug using Cyprumed's oral delivery technology, triggering a milestone payment. If successful, this could let Merck turn injectable peptides into pills, a big manufacturing and patient convenience advantage that supports the pipeline.
New technology milestone that could improve drug delivery and extend product lifecycles.
AstraZeneca's $2B bet on Keytruda rival Summit AstraZeneca will invest $2 billion in Summit Therapeutics and lead trials combining Summit's ivonescimab with AstraZeneca's cancer drugs. Ivonescimab has already beaten Keytruda in lung cancer survival, so this deepens the competitive threat to Merck's biggest franchise ahead of its 2028 patent expiry.
New competitive escalation directly pressures Keytruda, Merck's largest revenue source.

20 Sep – 25 Sep 2026

▲3▼1

Merck's Label Wins and Pipeline Progress Offset Keytruda Competition

Multiple FDA and global label expansions for Keytruda, Winrevair, and Welireg Merck won FDA label updates for Winrevair (adding Phase 3 HYPERION data showing 76% reduction in clinical worsening) and Welireg plus Lenvima for advanced kidney cancer, plus Japanese approval for subcutaneous Keytruda across all indications. These expand approved uses and strengthen revenue durability.
These regulatory wins directly broaden Merck's product labels and market reach, supporting future sales growth.
Pipeline advances in remigromig and Keytruda combinations Merck's remigromig met its primary goal in a Phase IIb/III diabetic macular edema study, a first-in-class eye drug. Also, Inhibrx's INBRX-106 combined with Keytruda nearly doubled response rates in head and neck cancer, reinforcing Keytruda's backbone role.
These pipeline successes show Merck's R&D engine is producing new growth drivers beyond current drugs.
Keytruda faces competitive and regulatory setbacks Summit's ivonescimab cut death risk 27% versus Keytruda in lung cancer, a direct threat. Separately, Merck and Daiichi Sankyo withdrew a US application for ifinatamab deruxtecan after FDA said data didn't support accelerated approval, delaying a pipeline candidate.
These events pressure Keytruda's dominance and remove a near-term pipeline catalyst, weighing on sentiment.
Measles outbreak boosts demand for Merck's MMR vaccine A US measles outbreak with 3,471 cases and 95% in unvaccinated people increases demand for Merck's MMR vaccine. This provides a modest but steady revenue lift from an existing product.
Rising disease incidence directly drives higher vaccine sales for Merck.

7 Sep – 18 Sep 2026

▲3▼1

Merck's Pipeline Push and Keytruda Defense Drive the Story

Pipeline triples to offset Keytruda patent cliff Merck's phase III pipeline has nearly tripled since 2021, with 20 new drug launches expected by 2030 to replace Keytruda's 2028 patent loss. Acquisitions like Verona, Cidara and Terns add new growth. This reassures investors that the coming revenue drop may be a shallow dip, supporting the stock.
This is the central strategic force behind Merck's valuation and directly addresses its biggest risk.
Q2 sales beat, guidance raised, Keytruda strong Merck reported Q2 sales of $16.6 billion, with Keytruda franchise at $8.4 billion, and raised full-year 2026 guidance to $66.3–$67.3 billion. Winrevair jumped 75% to $588 million. Solid results and confident outlook support the stock, though a $5.7 billion acquisition charge caused a reported loss.
Earnings and guidance are key fundamental drivers that show current business strength and future expectations.
Keytruda rival shows survival advantage Summit's ivonescimab cut death risk by 27% versus Keytruda in a lung cancer trial, with an 8.2-month survival advantage. This is a direct competitive threat to Merck's biggest drug, pressuring the stock as it raises doubts about Keytruda's long-term dominance.
This is a major competitive development that could erode Keytruda's franchise, a core part of Merck's value.
EU approval advances Keytruda bladder cancer combo EU regulators gave a positive opinion for Keytruda plus Padcev in resectable muscle-invasive bladder cancer, with final approval expected by Q4 2026. This expands Keytruda's use into earlier-stage disease, adding a new revenue stream and strengthening the franchise.
Regulatory progress opens a new market for Keytruda, directly supporting future sales growth.

30 Aug – 4 Sep 2026

▲3▼1

Merck's mRNA cancer vaccine win lifts outlook, but Keytruda rivals close in

mRNA cancer vaccine success drives healthcare rally Merck and Moderna's personalized mRNA cancer vaccine met its main Phase 3 goal in melanoma, cutting recurrence when added to Keytruda. The news sparked a broad healthcare rally, with Merck up 12% in a day and the sector posting its best week since June. This opens a major new growth path for Merck's oncology business.
This is the biggest new event of the period, directly boosting Merck's growth outlook and stock.
Analysts see multi-billion sales potential for vaccine Barclays estimates the vaccine could generate up to $3 billion in annual melanoma sales by 2035, and the global melanoma drug market is projected to grow from $5.8 billion in 2024 to $10.3 billion by 2030. This supports expectations of a meaningful new revenue stream for Merck.
It quantifies the financial upside of the vaccine, which is key to why Merck's stock is moving.
LIPFENDRA approval opens high-growth cholesterol market Merck's LIPFENDRA, the first oral PCSK9 cholesterol drug, has been approved by the FDA, driving the PCSK9 inhibitor market into a high-growth phase. This adds a new cardiometabolic pillar to Merck's business, diversifying revenue beyond Keytruda and supporting long-term growth.
It shows a new approved product expanding Merck's revenue base, which investors view positively.
Keytruda biosimilar and rival lung cancer threat Cipla's US unit secured exclusive rights to commercialize a proposed pembrolizumab biosimilar ahead of Keytruda's 2028 patent expiry. Separately, Summit Therapeutics' ivonescimab showed superior overall survival versus Keytruda in a lung cancer trial. These developments increase competition and pressure Merck's biggest franchise.
It is the main counterweight to the positive news, highlighting risks to Merck's key revenue source.

August 202627 Jul – 28 Aug 2026

▲2▼2

Merck beats Q2, raises guidance, but acquisition charges and mRNA vaccine risks temper outlook

Q2 Beat and Raised Guidance Merck reported Q2 revenue of $16.61 billion, beating estimates, and raised its full-year 2026 revenue guidance to $66.3–67.3 billion, signaling confidence in its core business.
This is a new positive development that directly supports the stock by showing better-than-expected financial performance and improved future outlook.
mRNA Cancer Vaccine Phase 3 Win Merck and Moderna's mRNA cancer vaccine succeeded in a Phase 3 melanoma trial, the first such win, with analysts projecting up to $54 billion in peak sales and testing in nine cancer trials.
This is a major new pipeline breakthrough that could drive long-term growth and is a key reason for investor optimism.
Acquisition Charges Cause Quarterly Loss Multibillion-dollar charges from acquisitions of Bio-Techne, Cidara, and Terns pushed Merck to a quarterly loss, pressuring reported earnings despite the revenue beat.
This new negative factor explains why reported earnings were weak and could weigh on investor sentiment.
mRNA Vaccine Unapproved and Biotech Volatility The mRNA cancer vaccine remains unapproved, so revenue depends on regulatory review, and Moderna's 20% post-surge plunge highlights the volatility of biotech stocks, adding uncertainty.
This new risk factor tempers the positive vaccine news and could lead to stock price swings.

8 Aug – 28 Aug 2026

▲3

Merck Hits 52-Week High on mRNA Cancer Vaccine Win and Pipeline Push

First Phase 3 win for mRNA cancer vaccine with Moderna Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.
This is the biggest new catalyst driving MRK's stock to a 52-week high.
Analysts see multi-billion sales potential for the vaccine Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.
Analyst upgrades and sales estimates directly influence investor expectations and stock price.
Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.
Pipeline expansion reduces reliance on Keytruda and supports long-term growth narrative.
Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.
This counterweight reminds investors that the vaccine is not yet approved and near-term revenue is uncertain.

19 Aug – 20 Aug 2026

▲3

Merck Jumps on First mRNA Cancer Vaccine Win with Moderna

Phase 3 mRNA cancer vaccine success Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.
This is the single new event that drove Merck's stock up over 11% and sets up a potential new product.
Analysts see multi-billion sales potential Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.
Analyst estimates quantify the financial upside for Merck, reinforcing the positive stock reaction.
Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.
It shows the win is not a one-off but part of a larger strategy that could drive long-term growth.
Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.
It provides a fair counterweight: the excitement is justified but not without risk, and Merck's own stock move was more measured.

27 Jul – 6 Aug 2026

▲3

Merck Beats Q2, Raises Guidance as Keytruda and New Drugs Expand

Q2 Beat and Raised 2026 Guidance Merck reported Q2 revenue of $16.61 billion, up 5% and above estimates, with Keytruda sales of $8.37 billion. Management raised full-year 2026 revenue guidance to $66.3–$67.3 billion. This directly boosts investor confidence and supports a higher stock price.
This is the period's biggest new financial catalyst, showing stronger-than-expected results and a brighter outlook.
Keytruda Label Expansions in Canada and EU Diagnostic Health Canada approved Keytruda with enfortumab vedotin for bladder cancer, and Agilent's EU companion diagnostic helps identify more patients for Keytruda. These expand Keytruda's use into new patient groups, supporting future sales growth as Merck faces eventual patent expiration.
New approvals and diagnostic tools widen Keytruda's market, a key growth driver for Merck.
New Drug Approvals and Pipeline Progress FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, adding a new cardiometabolic pillar. Merck also advanced HIV prevention access and reported positive Phase 3 results for a once-weekly HIV regimen. These diversify revenue beyond Keytruda and support long-term growth.
These new products and pipeline wins show Merck building future revenue streams, reducing reliance on Keytruda.
Acquisition Charges Weigh on Reported Earnings Merck's $11.3 billion Bio-Techne and $9 billion Cidara acquisitions, plus a $5.7 billion Terns charge, caused a reported quarterly loss. While these deals aim to replenish the pipeline, the large cash outlays and charges pressure near-term reported profits and could weigh on sentiment.
This is the main counterweight: big spending and accounting losses offset strong operational results.

July 202630 Jun – 24 Jul 2026

▲2▼2

Merck's Pipeline Wins Offset Generic and Regulatory Pressures

Keytruda Label Expansion and Phase 3 Win Keytruda won U.S. and EU approvals in breast and bladder cancer and succeeded in a Phase 3 endometrial cancer trial, expanding its use and supporting future sales.
This is a major new positive driver for Merck's top-selling drug.
New Drug Approvals and HIV Advancements The FDA approved LIPFENDRA, the first oral PCSK9 inhibitor, and Merck advanced HIV efforts with Gilead and an access plan, broadening its treatment portfolio.
These are new pipeline and label wins that could drive future revenue.
Congressional Probe into China Trials A U.S. House committee is investigating Merck's China clinical trials, raising concerns about ethics, data security, and intellectual property that could harm its reputation and operations.
This is a new regulatory and geopolitical risk that could weigh on the stock.
Generic Competition and COVID Revenue Loss Par Health launched a generic version of Janumet XR, eroding about $270 million in annual U.S. sales, while COVID-19 EUA termination removed Lagrevio revenue, pressuring overall sales.
These are new negative developments that directly reduce Merck's revenue.

15 Jul – 24 Jul 2026

▲3▼1

Merck's Pipeline Wins Outweigh Generic Erosion

Keytruda Endometrial Cancer Win Merck's Keytruda met its main goal in a Phase 3 endometrial cancer trial, showing better progression-free survival than chemotherapy. This expands Keytruda's use into a new cancer type, supporting future sales as the company faces patent expiration.
New clinical win expands Keytruda's label and supports long-term revenue.
FDA Approves First Oral PCSK9 Inhibitor LIPFENDRA Merck won FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor for high cholesterol. It cut LDL-C by up to 59% in trials and offers an easier option than injectables, opening a large new market for Merck.
New product approval opens a major new revenue stream beyond oncology.
HIV Pipeline Advances with Gilead and Access Plan Merck and Gilead reported positive Phase 3 results for a once-weekly oral HIV regimen, and Merck unveiled an early access plan for its once-monthly HIV prevention pill in 129 low- and middle-income countries. These moves strengthen Merck's HIV franchise and future demand.
New HIV data and access strategy expand Merck's pipeline and global reach.
Generic Janumet XR Launch Erodes Sales Par Health launched the first generic version of Merck's Janumet XR diabetes drug in the U.S. This will cut into Merck's sales of the branded product, which had about $270 million in annual U.S. revenue, as cheaper copies take market share.
New generic competition directly pressures an existing Merck product's revenue.

30 Jun – 10 Jul 2026

▲2▼2

Merck's Keytruda Label Wins Offset China Probe and COVID Drug Loss

U.S. House Committee Probes Merck's China Clinical Trials A House committee is investigating Merck's clinical trials at Chinese military sites and in Xinjiang, raising concerns about ethics, data security, and intellectual property. This regulatory and headline risk could weigh on the stock, especially if it leads to restrictions or reputational damage.
This is a new negative regulatory event that introduces uncertainty and potential downside for MRK.
COVID-19 EUA Termination Hits Merck's Lagrevio The U.S. government ended emergency use authorizations for COVID-19 drugs, including Merck's Lagrevio. This removes a revenue stream and could lower future sales expectations, though the impact may be limited if COVID-19 remains endemic and traditional approvals are pursued.
This is a new regulatory change that directly reduces Merck's COVID-19 product sales.
Keytruda Wins New U.S. and EU Approvals in Breast and Bladder Cancer Merck received FDA and EU approvals for Keytruda-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer, including a subcutaneous form. These expand Keytruda's label into earlier and tougher tumors, supporting sales growth as the company prepares for patent expiration.
These new approvals broaden Keytruda's market and reinforce Merck's oncology strategy, a key positive driver.
Tulisokibart Phase 3 Success Strengthens Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met its main goal in a Phase 3 ulcerative colitis trial. This is a first for this drug class and helps diversify Merck beyond oncology, offsetting future Keytruda competition and supporting long-term growth.
This pipeline win is a new positive development that boosts Merck's diversification efforts.

Q2 202617 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

June 202617 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

17 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

Gilead Sciences Inc (GILD)

Q3 20266 Jul – 22 Sep 2026

▲3▼1

Gilead Q3: HIV strength, new launches, but big writedown weighs

Q2 revenue up 10%, HIV sales up 12%, guidance raised Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12%, and the company raised its full-year guidance. This shows the core business is growing and management is more confident about the future.
This is the main positive force behind the stock this quarter, showing stronger sales and a brighter outlook.
Four planned launches and new approvals broaden business beyond HIV Gilead is preparing four new product launches and won approvals for Bixlenvo and a Trodelvy/Keytruda combination. This diversification reduces reliance on HIV and opens new revenue streams, which supports the stock.
It shows concrete progress in expanding beyond HIV, a key part of the bull case this quarter.
Legal win protects Biktarvy; PAHO deal expands lenacapavir access Gilead won a legal case protecting its key HIV drug Biktarvy from generic competition, and signed a deal with PAHO to expand access to lenacapavir. These reduce competitive threats and open new markets, helping the stock.
These events remove a major risk and add a growth avenue, both new this quarter.
$11.2B acquired IPR&D charge causes $8.45 GAAP loss Gilead reported a GAAP loss of $8.45 per share due to an $11.2 billion charge for acquired in-process research and development. This accounting charge weighed on reported earnings, though it doesn't reflect cash flow or ongoing operations.
It is the main negative factor this quarter, explaining why reported earnings looked bad despite strong sales.

September 20265 Sep – 22 Sep 2026

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.
This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.
PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.
This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.
Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.
Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.
Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.
Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Latest5 Sep – 22 Sep 2026

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.
This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.
PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.
This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.
Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.
Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.
Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.
Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

August 202629 Jul – 27 Aug 2026

▲3▼1

Gilead Q2 beat, HIV strength, new drug approvals, but accounting loss

Q2 earnings beat and raised guidance Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12% and PrEP topping $1 billion. The company raised its full-year HIV growth outlook to 9–10%, signaling confidence.
This is the main positive force behind the stock, showing strong operational performance.
New HIV and cancer drug approvals The FDA approved Bixlenvo, a new single-tablet HIV regimen, and the EU expanded Trodelvy plus Keytruda for first-line triple-negative breast cancer. These expand Gilead's product lineup and market reach.
These approvals are new revenue drivers and reinforce Gilead's competitive position.
Large accounting loss from acquisitions Gilead reported a GAAP loss of $8.45 per share due to $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines. This is an accounting charge, not an operational loss, but it weighed on reported earnings.
This explains the headline loss and why it may not reflect underlying business health.
Analyst confidence and pipeline progress BofA reiterated a Buy rating with a $162 target, and Gilead advanced its pipeline in oncology and a once-weekly oral HIV regimen. However, these pipeline gains are early and not yet near-term revenue.
Analyst support and pipeline advances support the stock, though with limited immediate impact.

15 Aug – 27 Aug 2026

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.
This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.
FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.
A new product approval expands the addressable market and future revenue, directly lifting growth prospects.
European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.
A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.
Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.
New pipeline additions signal longer-term growth potential, which can support a higher valuation.

29 Jul – 13 Aug 2026

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.
This is the period's central event and directly explains the positive fundamental momentum behind GILD.
PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.
It highlights a key new growth driver that is boosting investor confidence and future sales.
Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.
It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.
Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.
It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 20266 Jul – 24 Jul 2026

▲4

Gilead's pipeline expands with new launches and positive HIV data

Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.
This is a new strategic update that shows Gilead's growth beyond its core HIV business.
Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.
This is a new clinical milestone that could lead to a new product and boost future sales.
CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.
This is a new regulatory step that could lead to approval and broader use of a key drug.
Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.
This is a new potential use for an existing drug, but the financial impact is not yet clear.

6 Jul – 24 Jul 2026

▲4

Gilead's pipeline expands with new launches and positive HIV data

Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.
This is a new strategic update that shows Gilead's growth beyond its core HIV business.
Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.
This is a new clinical milestone that could lead to a new product and boost future sales.
CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.
This is a new regulatory step that could lead to approval and broader use of a key drug.
Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.
This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 202617 Jun – 26 Jun 2026

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.
This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.
FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.
This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.
Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.
New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.
Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.
This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 202617 Jun – 26 Jun 2026

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.
This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.
FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.
This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.
Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.
New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.
Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.
This is a new negative financial disclosure that could cap upside from the positive pipeline news.

17 Jun – 26 Jun 2026

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.
This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.
FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.
This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.
Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.
New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.
Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.
This is a new negative financial disclosure that could cap upside from the positive pipeline news.